As a novel class of pharmaceuticals, nucleic acid drugs use DNA/RNA as active ingredients.
However, they present unique biosafety challenges: molecular instability, delivery risks, and manufacturing variability. To ensure safety, a comprehensive quality control system spanning raw materials to final products must be implemented using advanced analytical technologies.
